SCHEMBL257301

SCHEMBL257301

CC1OC(=O)C(O)=C1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9423146 1.00
SCHEMBL13092141 1.00
SCHEMBL29581947 0.97 MAPT (0.41)
SCHEMBL8749939 0.77
SCHEMBL15437684 0.77
SCHEMBL29281155 0.75
SCHEMBL29281154 0.75
SCHEMBL14938106 0.73 PPARG (0.43)
SCHEMBL2659803 0.72 AKT1 (0.35)
SCHEMBL382020 0.72 PTPN1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112544619-B Bactericidal composition 沈阳中化农药化工研发有限公司 2022-04-12 CN claimed
US-11789307-B2 Colorant filter, backlight unit, and liquid crystal display device FUJIFILM CORPORATION (JP) 2023-10-17 US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230144527-A1 STABLE ASCORBIC ACID COMPOSITIONS AND METHODS OF USING SAME RENOVION, INC. 2023-05-11 US disclosed
WO-2023076534-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2023076586-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
EP-3821249-B1 SPECIFIC BINDING CHEMILUMINESCENT ASSAY 3M INNOVATIVE PROPERTIES CO (US) 2022-06-29 EP disclosed
EP-3393990-B1 PEG-BINDER ROCKWOOL INT (DK) 2022-06-08 EP disclosed
US-11320424-B2 Specific binding chemiluminescent assay 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-05-03 US disclosed
CN-112544619-B Bactericidal composition 沈阳中化农药化工研发有限公司 2022-04-12 CN disclosed
WO-2007071966-A1 PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2007-06-28 WO disclosed
EP-1246811-B1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN LTD (GB) 2003-12-03 EP disclosed
US-6613919-B2 Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones OXIS ISLE OF MAN 2003-09-02 US disclosed
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones OXIS ISLE OF MAN 2003-04-03 US disclosed
EP-1246811-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS Isle of Man, Limited (GB) 2002-10-09 EP disclosed
WO-2001049671-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN, LIMITED (US) 2001-07-12 WO disclosed
EP-0938482-A1 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR Oxis International, Inc. (US) 1999-09-01 EP disclosed
WO-1998007714-A1 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR OXIS INTERNATIONAL, INC. (US) 1998-02-26 WO disclosed
US-5298526-A Optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids and pharmaceutical use THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1994-03-29 US disclosed
US-5095126-A Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1992-03-10 US disclosed